Methods for reducing lipase activity
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsXiaolin Tang, Leonid Breydo, John Mattila
Life of this patent
Estimating the term…
Loading patent…
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsXiaolin Tang, Leonid Breydo, John Mattila
Estimating the term…
Pharmaceutical formulations comprising an antibody that specifically binds to human interleukin-4 receptor alpha (hIL-4Rα) are provided. The formulations may contain, in addition to an anti-IL-4Rα antibody, one or more buffers, at least one amino acid, at least one sugar, and a surfactant comprising a polysorbate, polyethylene glycol or a poloxamer. Methods for producing pharmaceutical formulations with reduced lipase activity are also provided, which may include subjecting a drug substance to anion exchange chromatography in acidic conditions, agitation stress, heat stress, and additional ion exchange or size exclusion chromatography. In one aspect, the pharmaceutical formulations do not have appreciable subvisible particle formation in the presence of lipase, and exhibit a substantial degree of antibody stability during storage and after being subjected to thermal and other physical stresses.
A method for producing a pharmaceutical composition with reduced lipase activity, comprising:
A method for producing a pharmaceutical composition with reduced lipase activity, comprising:
Dependencies are inferred from the claim text.